Sigilon Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2020 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Sigilon Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2020 to Q1 2023.
  • Sigilon Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2023 was -$1.64M, a 3521% decline year-over-year.
  • Sigilon Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$1.61M, a 203% decline from 2021.
  • Sigilon Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $1.55M, a 99.2% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 -$1.64M -$1.69M -3521% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-09
Q1 2022 $48K +$525K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q1 2021 -$477K -$27.5M -102% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q1 2020 $27.1M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.